Corona: DRDO invites EOI to provide the technology of 2-DG medicine, this is the last date

Posted on 9th Jun 2021 by rohit kumar

The second wave of corona infection in the country has now come under control to a great extent. The Health Department is constantly trying to control the situation. The Defense Research and Development Organization (DRDO), which developed the drug 2-deoxy-D-glucose (2-DG), used in the treatment of Covid-19 patients, has decided to transfer the technology of making this drug to the Indian pharmaceutical industry. Expressions of Interest (EOIs) are invited.

 

 

The medicine helps in recovering from the disease faster

The 2-DG drug has been developed by DRDO's laboratory, Institute of Nuclear Medicine and Allied Sciences (INMAS) in association with Dr. Reddy Laboratories. Clinical trial results showed that it helps hospitalized patients recover faster and reduce their dependence on oxygen.

 

 

Application to be sent before June 17

As per the EOI document, applications should be sent through email before June 17. "The EoIs to be given by the industries will be examined by a Technical Assessment Committee (TAC)," it added. Only 15 industries will be given ToT based on their capabilities and first come first serve. The bidders should have a license to manufacture drugs from active pharmaceutical ingredients (APIs) from drug licensing authorities.

 

DRDO issued guidelines

DRDO had earlier issued guidelines regarding the use of 2-DG medicine. It has been clearly stated by the organization that this medicine should be given to the patients of Covid-19 only under the supervision and prescription of the doctors. In the guidelines issued by DRDO, it has been said that 2-DG medicine is only for emergency use of corona patients. This drug should be used as adjunctive therapy in hospitalized corona patients. It should be used only based on the advice of doctors for the treatment of moderate and severe patients of the corona. Do not take this medicine without medical advice.

Other news